Figure 3.

Evolution of In Vivo Models to Evaluate Hypoimmunogenicity of Genetically Engineered Pluripotent Stem Cells

(A) Size of teratomas measured following injection of engineered cells into immunocompetent mice to evaluate mouse cell engraftment.

(B) NSG mice injected with engineered cells plus T cells before measurement of teratoma size.

(C) To recapitulate the human immune system, human HSCs transplanted into NSG mice and injected with the engineered cells.

(D) To promote T cell reconstitution, maturation, and selection, human HSC cells, fetal liver, and fetal thymus tissue transplanted into NSG mice before injection with the engineered cells to evaluate immunogenicity.